CYDY
Price
$0.35
Change
+$0.01 (+2.94%)
Updated
Jun 6 closing price
Capitalization
420.88M
51 days until earnings call
GNMSF
Price
$218.13
Change
+$6.12 (+2.89%)
Updated
Jun 5 closing price
Capitalization
13.52B
Interact to see
Advertisement

CYDY vs GNMSF

Header iconCYDY vs GNMSF Comparison
Open Charts CYDY vs GNMSFBanner chart's image
CytoDyn
Price$0.35
Change+$0.01 (+2.94%)
Volume$1.02M
Capitalization420.88M
Genmab A/S
Price$218.13
Change+$6.12 (+2.89%)
Volume$6
Capitalization13.52B
CYDY vs GNMSF Comparison Chart
Loading...
CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYDY vs. GNMSF commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYDY is a Hold and GNMSF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (CYDY: $0.34 vs. GNMSF: $209.74)
Brand notoriety: CYDY and GNMSF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYDY: 79% vs. GNMSF: 2%
Market capitalization -- CYDY: $420.88M vs. GNMSF: $13.52B
CYDY [@Biotechnology] is valued at $420.88M. GNMSF’s [@Biotechnology] market capitalization is $13.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYDY’s FA Score shows that 1 FA rating(s) are green whileGNMSF’s FA Score has 0 green FA rating(s).

  • CYDY’s FA Score: 1 green, 4 red.
  • GNMSF’s FA Score: 0 green, 5 red.
According to our system of comparison, CYDY is a better buy in the long-term than GNMSF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYDY’s TA Score shows that 5 TA indicator(s) are bullish while GNMSF’s TA Score has 4 bullish TA indicator(s).

  • CYDY’s TA Score: 5 bullish, 5 bearish.
  • GNMSF’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CYDY is a better buy in the short-term than GNMSF.

Price Growth

CYDY (@Biotechnology) experienced а -6.06% price change this week, while GNMSF (@Biotechnology) price change was +0.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

CYDY is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMSF($13.5B) has a higher market cap than CYDY($421M). CYDY YTD gains are higher at: 207.511 vs. GNMSF (1.140). GNMSF has higher annual earnings (EBITDA): 9.7B vs. CYDY (-1.98M). GNMSF has more cash in the bank: 21.1B vs. CYDY (16.4M). CYDY has less debt than GNMSF: CYDY (27.3M) vs GNMSF (1.03B). GNMSF has higher revenues than CYDY: GNMSF (21.5B) vs CYDY (0).
CYDYGNMSFCYDY / GNMSF
Capitalization421M13.5B3%
EBITDA-1.98M9.7B-0%
Gain YTD207.5111.14018,196%
P/E RatioN/A12.80-
Revenue021.5B-
Total Cash16.4M21.1B0%
Total Debt27.3M1.03B3%
FUNDAMENTALS RATINGS
CYDY vs GNMSF: Fundamental Ratings
CYDY
GNMSF
OUTLOOK RATING
1..100
7127
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10041
PRICE GROWTH RATING
1..100
3558
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYDY's Valuation (4) in the null industry is somewhat better than the same rating for GNMSF (60). This means that CYDY’s stock grew somewhat faster than GNMSF’s over the last 12 months.

CYDY's Profit vs Risk Rating (100) in the null industry is in the same range as GNMSF (100). This means that CYDY’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's SMR Rating (41) in the null industry is somewhat better than the same rating for CYDY (100). This means that GNMSF’s stock grew somewhat faster than CYDY’s over the last 12 months.

CYDY's Price Growth Rating (35) in the null industry is in the same range as GNMSF (58). This means that CYDY’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's P/E Growth Rating (94) in the null industry is in the same range as CYDY (100). This means that GNMSF’s stock grew similarly to CYDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYDYGNMSF
RSI
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 27 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 27 days ago
66%
Momentum
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 27 days ago
79%
MACD
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 27 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 27 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 27 days ago
72%
Advances
ODDS (%)
Bullish Trend 26 days ago
85%
Bullish Trend about 1 month ago
65%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend about 1 month ago
73%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 27 days ago
80%
Aroon
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 27 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

CYDY and

Correlation & Price change

A.I.dvisor tells us that CYDY and RGLS have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYDY and RGLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYDY
1D Price
Change %
CYDY100%
+3.70%
RGLS - CYDY
25%
Poorly correlated
+0.25%
TNXP - CYDY
22%
Poorly correlated
+1.89%
AGNPF - CYDY
21%
Poorly correlated
-9.31%
CLNN - CYDY
20%
Poorly correlated
+0.76%
GNNSF - CYDY
16%
Poorly correlated
N/A
More

GNMSF and

Correlation & Price change

A.I.dvisor tells us that GNMSF and SLN have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNMSF and SLN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
-0.17%
SLN - GNMSF
24%
Poorly correlated
+3.80%
ABOS - GNMSF
20%
Poorly correlated
N/A
CYDY - GNMSF
14%
Poorly correlated
+3.70%
CVALF - GNMSF
9%
Poorly correlated
-4.41%
CMVLF - GNMSF
7%
Poorly correlated
N/A
More